Aura Biosciences to Participate in Upcoming Investor Conferences

GlobeNewswire

02-25

BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:

TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025.
Fireside Chat at 9:10 a.m. ET.
Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025.
Fireside Chat at 8:00 a.m. ET.

The live webcasts of both fireside chats will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of each webcast will be archived for 90 days following the presentation date.

About Aura Biosciences

Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura Biosciences is headquartered in Boston, MA. Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients.

For more information, visit aurabiosciences.com. Follow us on X (formerly Twitter) @AuraBiosciences and visit us on LinkedIn.

Investor and Media Contact:
Alex Dasalla
Head of Investor Relations and Corporate Communications
IR@aurabiosciences.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2514683095"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514683095\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2514683095?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514683095","market":"hk","top_or_hot":-1,"title":"Aura Biosciences to Participate in Upcoming Investor Conferences","media":"GlobeNewswire","content":"<html><body><p>BOSTON, Feb.  25, 2025  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/AURA\">Aura Biosciences, Inc.</a> (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:</p> <ul type=\"disc\"><li><strong>TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025.</strong><br/>Fireside Chat at 9:10 a.m. ET.</li><li><strong>Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025. </strong><br/>Fireside Chat at 8:00 a.m. ET.</li></ul> <p>The live webcasts of both fireside chats will be available on the “Investors &amp; Media” page under the “Events &amp; Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of each webcast will be archived for 90 days following the presentation date.</p> <p><strong>About Aura Biosciences</strong></p> <p>Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura Biosciences is headquartered in Boston, MA. Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients.</p> <p>For more information, visit aurabiosciences.com. Follow us on X (formerly Twitter) @AuraBiosciences and visit us on LinkedIn.</p> <p><strong>Investor and Media Contact:</strong><br/>Alex Dasalla<br/>Head of Investor Relations and Corporate Communications<br/>IR@aurabiosciences.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/ZmM2ZDI5N2ItMmQwZS00NTQ0LThhZmItYjdjOWQzNGMyZWE3LTUwMDEyNDI2MA==/tiny/Aura-Biosciences-Inc-.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aura Biosciences to Participate in Upcoming Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAura Biosciences to Participate in Upcoming Investor Conferences\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time smaller\">2025-02-25 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p>BOSTON, Feb.  25, 2025  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/AURA\">Aura Biosciences, Inc.</a> (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:</p> <ul type=\"disc\"><li><strong>TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025.</strong><br/>Fireside Chat at 9:10 a.m. ET.</li><li><strong>Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025. </strong><br/>Fireside Chat at 8:00 a.m. ET.</li></ul> <p>The live webcasts of both fireside chats will be available on the “Investors &amp; Media” page under the “Events &amp; Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of each webcast will be archived for 90 days following the presentation date.</p> <p><strong>About Aura Biosciences</strong></p> <p>Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura Biosciences is headquartered in Boston, MA. Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients.</p> <p>For more information, visit aurabiosciences.com. Follow us on X (formerly Twitter) @AuraBiosciences and visit us on LinkedIn.</p> <p><strong>Investor and Media Contact:</strong><br/>Alex Dasalla<br/>Head of Investor Relations and Corporate Communications<br/>IR@aurabiosciences.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/ZmM2ZDI5N2ItMmQwZS00NTQ0LThhZmItYjdjOWQzNGMyZWE3LTUwMDEyNDI2MA==/tiny/Aura-Biosciences-Inc-.png\"/></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2025/02/25/3031830/0/en/Aura-Biosciences-to-Participate-in-Upcoming-Investor-Conferences.html","article_id":"2514683095","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514683095","pubTimestamp":1740484800,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"BOSTON, Feb.  25, 2025  (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ fun","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AURA":"Aura Biosciences, Inc."},"translate_title":"Aura Biosciences将参加即将举行的投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AURA":1},"content_text":"BOSTON, Feb.  25, 2025  (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025.Fireside Chat at 9:10 a.m. ET.Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025. Fireside Chat at 8:00 a.m. ET. The live webcasts of both fireside chats will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of each webcast will be archived for 90 days following the presentation date. About Aura Biosciences Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura Biosciences is headquartered in Boston, MA. Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients. For more information, visit aurabiosciences.com. Follow us on X (formerly Twitter) @AuraBiosciences and visit us on LinkedIn. Investor and Media Contact:Alex DasallaHead of Investor Relations and Corporate CommunicationsIR@aurabiosciences.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}